Each participant donated a venous blood sample, an overnight urine sample, and a fecal sample for microbiome analysis at baseline before treatment initiation, after 1 month, 3 months, and 12 months of treatment
That means that your plan will be customized to your unique needs
Gastroenterol., 2007
98 The reasons behind the discordant results in the cardiovascular outcomes in the use of GLP-1R agonists in humans with T2DM are likely multifactorial, including heterogeneity in disease, patient population and treatment regimens, and a lack of bioequivalence among the agents
Medications such as metformin or SGLT2 inhibitors, when indicated for glycaemic control, may have modest weight-neutral or weight-reducing effects
Our helpful clinic staff can assist you in verifying your benefits or discussing alternative self-pay pricing options